Peer AI Taps Veeva Veteran to Scale Agentic AI in Life Sciences

SAN FRANCISCO, CA – January 26, 2026 – As the life sciences industry accelerates its shift from artificial intelligence pilots to full-scale production, agentic AI platform Peer AI has appointed David Florez, a seasoned executive from Veeva Systems, as its new Vice President of Sales. The strategic hire signals the company's intent to aggressively expand its market footprint and guide pharmaceutical companies through the complex process of automating regulatory documentation.

Florez will spearhead the go-to-market strategy for Peer AI, a company that has gained traction by using specialized AI agents to drastically reduce the time and effort required for creating critical regulatory documents. His appointment comes at what many industry observers call a crucial inflection point, where the theoretical promise of AI is finally translating into measurable results within highly regulated workflows.

A Strategic Hire for a Critical Inflection Point

The decision to bring Florez on board is a calculated move to capitalize on a burgeoning market. Life sciences organizations are increasingly looking for purpose-built AI solutions that can deliver tangible returns on investment, particularly in areas plagued by bottlenecks. Regulatory documentation—a notoriously slow, complex, and document-intensive process—is a prime target for this technological disruption.

"AI implementation requires world-class technology and governance, validation, change management, and organizational alignment to drive change," said Anita Modi, CEO and co-founder of Peer AI, in a statement. "David has deep life sciences expertise and proven go-to-market success helping customers navigate transitions during major waves of technology innovation. As more companies embrace the shift to an intelligent regulatory workflow, David's experience will be instrumental in driving customer success and helping Peer AI enter its next phase of growth."

Florez’s six-year tenure in a senior sales role at Veeva Systems is particularly relevant. At Veeva, he was instrumental in partnering with pharma and biotech leaders to implement cloud solutions across clinical, regulatory, and quality domains. This experience in scaling mission-critical technology within the industry's stringent compliance frameworks provides him with a unique perspective on the challenges and opportunities Peer AI faces.

"I've seen companies struggle with the same documentation bottlenecks, even with the world's best content and data management systems," Florez stated. "Regulatory documentation slows drug development down. It's an area ripe for change and Peer AI is leading the way. I'm committed to helping the industry experience the value of agentic AI and move to a new frontier in how this critical work gets done."

Beyond Generative AI: The Rise of the Agentic Platform

Peer AI's competitive edge lies in its sophisticated application of agentic AI, a significant leap beyond the capabilities of general-purpose generative AI tools. While generative AI can create content based on prompts, agentic AI systems are designed to autonomously plan, reason, and execute complex, multi-step tasks to achieve a specific goal, all while operating under human oversight.

These platforms deploy a team of specialized AI agents that work in concert. For instance, a data source agent might extract information from clinical trial results, an authoring agent crafts the initial draft of a Clinical Study Report (CSR), a style agent ensures compliance with company-specific formatting, and a post-processing agent conducts final validation checks. This orchestrated workflow mimics and accelerates the work of a human team.

The growing legitimacy of this approach is underscored by its adoption within regulatory bodies themselves. In December 2025, the U.S. Food and Drug Administration (FDA) deployed its own agentic AI platform to support tasks across pre-market reviews, inspections, and compliance. This move signals a broader acceptance of agentic systems as a reliable tool for managing the complexities of modern regulation.

Peer AI's platform is built on this principle of human-AI collaboration. It provides an intuitive interface that allows medical writers and subject matter experts to guide the AI, apply their expertise at critical control points, and maintain ultimate control over the final output. This 'human-in-the-loop' model is essential for ensuring accuracy, integrity, and compliance in a field where errors can have profound consequences.

From Theory to Practice: Validating a Revolution in Regulatory Writing

Backed by a $12.1 million funding round in October 2025 led by Flare Capital Partners and SignalFire, Peer AI has moved quickly to prove its value proposition with tangible results. The company reports that its platform usage grew significantly in 2025, with daily active use tripling and overall platform volume increasing sixfold.

Client data and testimonials provide compelling evidence of the platform's impact. Customers have reported accelerating document drafting times by 55% to as much as 94%. In one case, the time to produce a first draft of a CSR was reduced from 40 days to just 17. A mid-sized biotech using the platform for its Chemistry, Manufacturing, and Controls (CMC) documentation achieved a 60% faster turnaround for its Module 3 workflows.

Quality improvements are equally significant. A joint presentation with Biogen at the CNS Summit 2025 highlighted a year-long collaboration where Peer AI's platform produced CSR drafts that were not only faster but also of higher quality, reducing the burden of subsequent review cycles. Another client noted that summaries of clinical safety generated by the platform were "effectively indistinguishable from a first draft written manually," with one user stating the AI-generated version had superior formatting to their own templates.

These results demonstrate that the technology is delivering on its promise, transforming a traditionally arduous process into a streamlined, efficient workflow that empowers human experts rather than replacing them.

Navigating the Hurdles of AI Adoption

Despite the clear potential, the path to widespread AI adoption in life sciences is not without obstacles. Industry analysts from Gartner have pointed out that while AI technology is ready, organizational data often is not. Poor data quality and fragmented systems can hinder even the most advanced algorithms. Furthermore, a 2025 Deloitte study found that while many organizations are piloting agentic AI, only 11% are actively using it in production, highlighting a significant gap between exploration and implementation.

This is precisely the landscape Florez is being tasked to navigate. His role will extend beyond sales to encompass change management and strategic partnership, helping clients build the governance and validation frameworks necessary to move from small-scale pilots to enterprise-wide deployment. With industry experts predicting that AI could ultimately reduce overall drug development timelines by up to 30%, the stakes for getting this transition right are immense.

As Peer AI prepares to showcase its platform at the upcoming DIA Regulatory Submissions, Information, and Document Management (RSIDM) Forum in February, the appointment of Florez marks a clear statement of intent. The company is positioning itself not just as a technology vendor, but as a crucial partner for an industry on the cusp of a new, AI-driven frontier.